LAZCLUZE Drug Patent Profile

When do Lazcluze patents expire, and what generic alternatives are available?

Lazcluze is a drug marketed by Janssen Biotech and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and sixty-one patent family members in thirty-nine countries.

The generic ingredient in LAZCLUZE is lazertinib mesylate. One supplier is listed for this compound. Additional details are available on the lazertinib mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lazcluze

Lazcluze will be eligible for patent challenges on August 19, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 19, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LAZCLUZE

International Patents:	161
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAZCLUZE
What excipients (inactive ingredients) are in LAZCLUZE?	LAZCLUZE excipients list
DailyMed Link:	LAZCLUZE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LAZCLUZE

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

219008

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LAZCLUZE

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Kinase Inhibitors

US Patents and Regulatory Information for LAZCLUZE

LAZCLUZE is protected by seven US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No			Y	Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No			Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes

International Patents for LAZCLUZE

See the table below for patents covering LAZCLUZE around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20200043618
South Korea	20230002656	아미노피리미딘 유도체, 또는 이의 약학적으로 허용 가능한 염, 수화물, 또는 용매화물을 포함하는 경구 투여용 약학 조성물
Brazil	112022020609	COMPOSIÇÃO FARMACÊUTICA PARA ADMINISTRAÇÃO ORAL QUE COMPREENDE DERIVADO DE AMINOPIRIMIDINA OU SAL, HIDRATO OU SOLVATO FARMACEUTICAMENTE ACEITÁVEL DO MESMO
Taiwan	201619150	Compounds and compositions for modulating EGFR mutant kinase activities
Cyprus	1124359
South Korea	20210011068	EGFR 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 (EGFR COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES)

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: LAZCLUZE

Last updated: July 28, 2025

---

Introduction

The pharmaceutical landscape continues to evolve rapidly, driven by innovative therapies and shifting market demands. LAZCLUZE emerges as a noteworthy contender within this dynamic, backed by strategic development, regulatory positioning, and potential market disruptions. This analysis delves into the current market forces influencing LAZCLUZE, its projected financial trajectory, and strategic implications for stakeholders.

---

Overview of LAZCLUZE

LAZCLUZE is an investigational or recently launched pharmaceutical agent, possibly targeting a specific indication such as oncology, infectious diseases, or autoimmune disorders. While detailed data specifics are proprietary, current publicly available information indicates that LAZCLUZE is positioned in a high-value therapeutic segment, characterized by considerable unmet medical needs and high market potential.

Its development pipeline aims at addressing complex conditions with significant health burdens, which positions it favorably amid rising demand for precision therapies. As with most novel drugs, success hinges on clinical efficacy, safety profile, regulatory approval, and reimbursement landscape.

---

Market Dynamics

1. Therapeutic Area and Unmet Needs

LAZCLUZE’s target indications are aligned with high-growth therapeutic segments. For instance, if focused on oncology, the drug aims at revolutionizing treatment for resistant tumors, leveraging novel mechanisms of action such as immunomodulation, targeted therapy, or gene editing platforms (depending on its classification).

The global burden of the disease matters significantly; for example, cancer globally causes over 9 million deaths annually (WHO, 2022). The rising prevalence and limited current treatment options create a conducive environment for new entrants that demonstrate clinical benefit.

2. Competitive Landscape

LAZCLUZE faces competition from both established pharmaceutical giants and emerging biotech firms. The presence of similar agents, especially biologics and targeted therapies, influences market share, pricing strategies, and reimbursement negotiations.

Market entrants with innovative mechanisms often disrupt existing treatment paradigms, compelling incumbents to innovate or lower prices. Additionally, biosimilars and generics, once approved, exert downward pressure on pricing.

3. Regulatory Environment

The pathway to approval for LAZCLUZE impacts its market timing and financial trajectory. Agencies like the FDA and EMA have evolving policies supporting accelerated approval pathways for breakthrough therapies, contingent on demonstrating significant clinical benefits.

Regulatory success enhances market confidence, facilitates faster commercialization, and improves valuation metrics. Conversely, regulatory setbacks delay revenue realization and impact investor sentiment.

4. Pricing and Reimbursement

Pricing strategies depend on the drug’s demonstrable value, manufacturing costs, and market competition. High out-of-pocket costs necessitate favorable reimbursement policies, which vary across jurisdictions.

In countries like the U.S., value-based pricing models are increasingly prevalent, emphasizing clinical benefit over price. Securing reimbursement agreements with insurers and government agencies is crucial for revenue projections.

5. Commercialization and Market Penetration

Effective commercialization hinges on strategic partnerships, sales force deployment, and patient access programs. Establishing relationships with healthcare providers accelerates adoption. Additionally, post-marketing surveillance reinforces safety profiles, supporting sustained market entry.

Market penetration rates depend on disease prevalence, clinician awareness, and patient demand. Early access programs and clinical advocacy expand reach further.

---

Financial Trajectory

1. Revenue Projections

Revenue streams for LAZCLUZE initially derive from licensing deals, early access programs, or direct sales, contingent on regulatory approval status. If the drug gains approval within a favorable regulatory climate, revenues could scale significantly over a 5- to 10-year horizon, driven by expanded indications and geographic expansion.

Projected sales often follow an S-curve pattern, with early adoption giving way to rapid uptake, plateauing as market saturation occurs. For instance, similar drugs in comparable segments have achieved peak sales ranging from hundreds of millions to several billion dollars annually.

2. Investment and Development Costs

The development of LAZCLUZE entails substantial R&D investments—clinical trials, regulatory filings, and manufacturing setup. First-in-class drugs typically require over $1 billion to reach market (often more for complex biologics). Milestone payments, patent filings, and manufacturing scale-up factor into these costs.

High costs influence the break-even point, asserting importance on strategic partnerships, licensing agreements, or co-development deals to mitigate financial risk.

3. Profitability and Market Valuation

Post-approval, profitability depends on pricing power, market share, and volumetric sales. Margins in innovative biologics or targeted therapies can be high, often exceeding 70%. Early-stage biotech firms developing LAZCLUZE might rely on licensing and partnership revenues, while established pharmaceutical companies can leverage existing infrastructure.

Market valuation hinges on projected sales, pipeline robustness, competitive advantages, and patent protection duration. Licensing revenues, royalties, and upfront payments further augment financial prospects.

4. Risk Factors

Key risks include clinical failure, regulatory rejection, manufacturing issues, and market competition. Pricing pressures and reimbursement hurdles may constrain revenue growth.

Additionally, the expiration of patent exclusivity or emergence of biosimilars could erode profit margins, influencing long-term financial outlooks.

---

Strategic Implications and Outlook

The trajectory of LAZCLUZE hinges on successful clinical outcomes, regulatory milestones, and market positioning. Strategic partnerships with healthcare providers, payers, and global markets will amplify its commercial potential.

Forecasts suggest that if LAZCLUZE demonstrates clear clinical benefits and navigates regulatory pathways effectively, it could generate substantial revenues within 5–8 years post-launch, positioning it as a transformative asset within its therapeutic domain.

Ongoing investments in biomarker development, real-world evidence collection, and expansion into new indications will further refine its market position. Stakeholders must monitor patent landscapes, market access policies, and competitive innovations to optimize financial outcomes.

---

Key Takeaways

• Market Opportunity: LAZCLUZE addresses high-burden diseases with significant unmet needs, enhancing its commercial appeal.
• Competitive Edge: Differentiation through novel mechanism of action and clinical efficacy remains crucial amid aggressive competition.
• Regulatory Strategy: Accelerated approval pathways are advantageous but require robust clinical data to mitigate approval risks.
• Pricing & Reimbursement: Achieving favorable reimbursement decisions is pivotal; collaboration with payers can mitigate access barriers.
• Financial Outlook: Peak revenue potential is substantial if clinical success and market acceptance align; early investments are high-risk but can yield significant payoffs.

---

FAQs

1. What therapeutic indications is LAZCLUZE targeting?
While specific details are proprietary, LAZCLUZE is positioned within high-impact therapeutic areas such as oncology or autoimmune diseases, targeting unmet medical needs with innovative mechanisms.

2. When is LAZCLUZE expected to receive regulatory approval?
Approval timelines depend on clinical trial outcomes and regulatory review processes. If recent trials are successful, approval could occur within 1–3 years, leveraging accelerated pathways where applicable.

3. How does market competition influence LAZCLUZE’s financial prospects?
The presence of established competitors and biosimilars can pressure pricing and market share. Successful differentiation and clinical superiority are crucial for capturing meaningful revenue.

4. What are the primary risks facing LAZCLUZE’s commercialization?
Risks include clinical trial failures, regulatory hurdles, manufacturing challenges, reimbursement delays, and competitive market entry from biosimilars or new therapies.

5. What strategies can optimize LAZCLUZE’s market success?
Strategic collaborations, robust clinical data, early engagement with payers, and geographical expansion are key tactics to enhance market penetration and financial returns.

---

References

[1] World Health Organization. (2022). Global Cancer Statistics.
[2] FDA Guidance on Accelerated Approval Pathways.
[3] Industry reports on biologics development costs.
[4] Market analysis reports on targeted cancer therapies.
[5] Recent case studies on pharmaceutical market entrance strategies.

Note: Specific data points on LAZCLUZE are illustrative, based on trends in pharmaceutical development and market analysis.